Who Supplies Metformin to India from TURKEY

Importing finished pharmaceutical formulations containing Metformin into India requires compliance with the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The Central Drugs Standard Control Organization (CDSCO) mandates that both the drug and the manufacturing site be registered. For new drugs, approval under Rule 122E is necessary before registration or import. Applications for registration and import should be submitted to the Licensing Authority under the Act, i.e., the Drugs Controller General (I) at CDSCO.

Imported pharmaceutical formulations must undergo quality testing at CDSCO-approved laboratories. Batch-wise testing is required, with Certificates of Analysis (CoA) provided for each batch. Stability data must comply with International Council for Harmonisation (ICH) guidelines for Zone IV. The formulations must meet the standards set by the Indian Pharmacopoeia. Port inspections by customs drug inspectors are conducted to ensure compliance.

Between 2024 and 2026, the CDSCO has implemented regulatory updates affecting the import of finished pharmaceutical formulations. The Production Linked Incentive (PLI) scheme has been introduced to encourage domestic manufacturing, potentially impacting the volume of finished formulation imports. Bilateral agreements between India and Turkey have been established to facilitate pharmaceutical trade, including mutual recognition of Good Manufacturing Practices (GMP).

India imports finished Metformin formulations to meet the demand for patented and branded products, as well as specific dosage forms not produced domestically. The domestic capacity may not fulfill the entire market demand, leading to reliance on imports. The market size for Metformin formulations in India is substantial, driven by the prevalence of diabetes and the need for diverse formulations.

The import duty structure for pharmaceutical formulations under HS Code 30049099 includes a Basic Customs Duty of 10%, Education Cess of 2%, Secondary Higher Education Cess of 1%, and a Countervailing Duty (CVD) of 6%, totaling 17.10%. Additional taxes such as the Goods and Services Tax (GST) may apply. Exemptions and preferential rates may be available under specific conditions or agreements.

India sources finished Metformin formulations from Turkey due to competitive advantages such as patented formulations, specialized dosage forms, and high-quality manufacturing standards. Other suppliers include China, Germany, and the United States. Turkey's share in the Indian market is significant, offering unique formulations not readily available from other sources.

India imports Metformin formulations from Turkey due to strategic reasons such as access to patented formulations, specialized dosage forms, and technology-licensed products. Turkey supplies specific formulations that India does not manufacture domestically, fulfilling market needs and patient requirements.

Compared to other origins like China, the European Union, and the United States, Turkey offers competitive pricing, high-quality products, and reliable regulatory compliance. Turkey's unique advantage lies in its ability to provide specialized formulations and maintain consistent quality standards.

Indian importers face risks such as single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. Past shortages have occurred due to geopolitical tensions and logistical challenges. Mitigation strategies include diversifying suppliers and maintaining buffer stocks.

1. 1Engage in dual-sourcing strategies to reduce dependency on a single supplier.
2. 2Implement comprehensive inventory planning to manage supply chain disruptions.
3. 3Establish favorable payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Negotiate Minimum Order Quantities (MOQs) that align with demand forecasts.
5. 5Conduct thorough supplier qualification processes to ensure compliance with regulatory standards.

1. 1Obtain a Directorate General of Foreign Trade (DGFT) Importer Exporter Code (IEC).
2. 2Register the product with CDSCO using Form 40/41.
3. 3Secure a Drug Import License from the Licensing Authority.
4. 4Obtain a No Objection Certificate (NOC) from the Ministry of Health and Family Welfare.
5. 5Engage a Customs Broker for customs clearance procedures.
6. 6Seek an advance ruling for HS Code 30049099 to confirm classification and duty applicability.

1. 1Certificate of Analysis (CoA) for each batch.
2. 2Certificate of Pharmaceutical Product (CoPP).
3. 3Good Manufacturing Practice (GMP) certificate.
4. 4Drug Master File (DMF) for the product.
5. 5Stability data compliant with ICH Zone IVa/IVb guidelines.
6. 6Free Sale Certificate indicating the product is freely sold in the country of origin.
7. 7Manufacturer's authorization letter.

Upon arrival, customs drug inspectors conduct port inspections, including mandatory batch testing and sample collection. Timelines for testing vary, and if a batch fails, it may be rejected or require reprocessing. Common quality issues from Turkey include labeling discrepancies and stability concerns.

Annual renewal of CDSCO registration is mandatory. Periodic audits in Turkey ensure continued compliance with Indian regulations. Change control procedures must be documented, and pharmacovigilance systems should be in place. Post-import monitoring is required, and import records must be maintained as per the Drugs and Cosmetics Act.